{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:30:16Z","timestamp":1792791016812,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673658"],"award-info":[{"award-number":["81673658"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073859"],"award-info":[{"award-number":["82073859"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejphar.2023.175560","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T12:18:47Z","timestamp":1675253927000},"page":"175560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidney"],"prefix":"10.1016","volume":"943","author":[{"given":"Yan","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175560_bib1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2023.175560_bib2","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2023.175560_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.ejphar.2023.175560_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10557-018-6778-x","article-title":"Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes","volume":"32","author":"Birnbaum","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejphar.2023.175560_bib5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2119\/molmed.2012.00131","article-title":"MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages","volume":"18","author":"Braga","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejphar.2023.175560_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41419-020-2544-7","article-title":"Sodium-glucose cotransporter 2 inhibition suppresses HIF-1\u03b1-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice","volume":"11","author":"Cai","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2023.175560_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.apsb.2016.02.004","article-title":"The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases","volume":"6","author":"Chen","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejphar.2023.175560_bib8","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.4049\/jimmunol.181.6.4272","article-title":"RAGE ligation affects T cell activation and controls T cell differentiation","volume":"181","author":"Chen","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2023.175560_bib9","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2023.175560_bib10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.ijbiomac.2019.03.242","article-title":"Modulating the gut microbiota and inflammation is involved in the effect of Bupleurum polysaccharides against diabetic nephropathy in mice","volume":"132","author":"Feng","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejphar.2023.175560_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8570818","article-title":"Iron reduces M1 macrophage polarization in RAW264.7 macrophages associated with inhibition of STAT1","author":"Gan","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejphar.2023.175560_bib12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.kint.2021.09.005","article-title":"A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function","volume":"101","author":"Heerspink","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2023.175560_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2023.175560_bib14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.175560_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11892-018-0984-6","article-title":"Role of the immune system in diabetic kidney disease","volume":"18","author":"Hickey","year":"2018","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.ejphar.2023.175560_bib16","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1681\/ASN.2014050479","article-title":"IL-25 elicits innate lymphoid cells and multipotent progenitor type 2 cells that reduce renal ischemic\/reperfusion injury","volume":"26","author":"Huang","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2023.175560_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.tibs.2012.09.003","article-title":"The high mobility group box: the ultimate utility player of a cell","volume":"37","author":"Malarkey","year":"2012","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejphar.2023.175560_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcpa.2019.05.006","article-title":"Renal infiltration of macrophages in canine and feline chronic kidney disease","volume":"170","author":"Ohara","year":"2019","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.ejphar.2023.175560_bib19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.175560_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062218","article-title":"Glucose and blood pressure-dependent pathways-the progression of diabetic kidney disease","volume":"21","author":"Patel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.175560_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/diagnostics5020219","article-title":"Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases","volume":"5","author":"Pilzweger","year":"2015","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejphar.2023.175560_bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s11684-019-0719-3","article-title":"Correlation between serum miR-154-5p and urinary albumin excretion rates in patients with type 2 diabetes mellitus: a cross-sectional cohort study","volume":"14","author":"Ren","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2023.175560_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S2213-8587(21)00295-3","article-title":"Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials","volume":"10","author":"Rossing","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2023.175560_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9841-8_1","article-title":"Diabetic nephropathy: an overview","volume":"2067","author":"Sagoo","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2023.175560_bib25","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","article-title":"Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists","volume":"57","author":"Taal","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2023.175560_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/joim.12276","article-title":"High-mobility group box-1 in sterile inflammation","volume":"276","author":"Tsung","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejphar.2023.175560_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109411","article-title":"LncRNA GAS5 exacerbates renal tubular epithelial fibrosis by acting as a competing endogenous RNA of miR-96-5p","volume":"121","author":"Wang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2023.175560_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2543268","article-title":"The role of HMGB1 in the pathogenesis of type 2 diabetes","author":"Wang","year":"2016","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2023.175560_bib29","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4049\/jimmunol.168.3.1286","article-title":"In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation","volume":"168","author":"Wolfs","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2023.175560_bib30","article-title":"Bupleurum polysaccharides attenuates lipopolysaccharide-induced inflammation via modulating Toll-like receptor 4 signaling","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175560_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbagrm.2009.11.002","article-title":"The alarmin functions of high-mobility group proteins","volume":"1799","author":"Yang","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2023.175560_bib32","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.2119\/molmed.2015.00087","article-title":"High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule","volume":"21","author":"Yang","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejphar.2023.175560_bib33","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1038\/ncomms5436","article-title":"PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis","volume":"5","author":"Yang","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2023.175560_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijbiomac.2019.12.028","article-title":"The immunomodulatory role of irisin on osteogenesis via AMPK-mediated macrophage polarization","volume":"146","author":"Ye","year":"2020","journal-title":"Int. J. Biol. Macromol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:13:17Z","timestamp":1757977997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"alternative-id":["S0014299923000717"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175560","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidney","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175560"}}